Hauptseite > Publikationsdatenbank > Combining independent drug classes into superior, synergistically acting hybrid molecules > print |
001 | 12405 | ||
005 | 20200402205927.0 | ||
024 | 7 | _ | |2 pmid |a pmid:20922735 |
024 | 7 | _ | |2 DOI |a 10.1002/anie.201004437 |
024 | 7 | _ | |2 WOS |a WOS:000284045400042 |
024 | 7 | _ | |2 ISSN |a 0570-0833 |
024 | 7 | _ | |a altmetric:21805123 |2 altmetric |
037 | _ | _ | |a PreJuSER-12405 |
041 | _ | _ | |a eng |
082 | _ | _ | |a 540 |
084 | _ | _ | |2 WoS |a Chemistry, Multidisciplinary |
100 | 1 | _ | |0 P:(DE-HGF)0 |a Müller-Schiffmann, A. |b 0 |
245 | _ | _ | |a Combining independent drug classes into superior, synergistically acting hybrid molecules |
260 | _ | _ | |a Weinheim |b Wiley-VCH |c 2010 |
295 | 1 | 0 | |a Angewandte Chemie International Edition English |
300 | _ | _ | |a 8743 - 8746 |
336 | 7 | _ | |a Journal Article |0 PUB:(DE-HGF)16 |2 PUB:(DE-HGF) |
336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
336 | 7 | _ | |a ARTICLE |2 BibTeX |
336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
336 | 7 | _ | |a article |2 DRIVER |
440 | _ | 0 | |0 6077 |a Angewandte Chemie |v 49 |x 0044-8249 |y 46 |
500 | _ | _ | |a The major support for this work was from a grant of the Volkswagen-Stiftung to C. K., T. S., D. W., and H. S. (I/82 649); further funding was provided by EU-FP6 (cNEUPRO), EU-FP7 (PRIORITY) grants to C. K. and a DFG-GRK1033 grant to J.K. and C. K. |
536 | _ | _ | |0 G:(DE-Juel1)FUEK409 |2 G:(DE-HGF) |a Funktion und Dysfunktion des Nervensystems |c P33 |x 0 |
536 | _ | _ | |0 G:(DE-Juel1)FUEK505 |2 G:(DE-HGF) |a BioSoft: Makromolekulare Systeme und biologische Informationsverarbeitung |c P45 |x 1 |
588 | _ | _ | |a Dataset connected to Web of Science, Pubmed |
650 | _ | 2 | |2 MeSH |a Amino Acid Sequence |
650 | _ | 2 | |2 MeSH |a Amyloid beta-Peptides: chemistry |
650 | _ | 2 | |2 MeSH |a Animals |
650 | _ | 2 | |2 MeSH |a CHO Cells |
650 | _ | 2 | |2 MeSH |a Cricetinae |
650 | _ | 2 | |2 MeSH |a Cricetulus |
650 | _ | 2 | |2 MeSH |a Drug Design |
650 | _ | 2 | |2 MeSH |a Humans |
650 | _ | 2 | |2 MeSH |a Immunoprecipitation |
650 | _ | 2 | |2 MeSH |a Oligopeptides: chemistry |
650 | _ | 2 | |2 MeSH |a Oligopeptides: pharmacology |
650 | _ | 2 | |2 MeSH |a Protein Structure, Secondary |
650 | _ | 2 | |2 MeSH |a Pyrazoles: chemistry |
650 | _ | 2 | |2 MeSH |a Stereoisomerism |
650 | _ | 7 | |0 0 |2 NLM Chemicals |a Amyloid beta-Peptides |
650 | _ | 7 | |0 0 |2 NLM Chemicals |a D3 peptide |
650 | _ | 7 | |0 0 |2 NLM Chemicals |a Oligopeptides |
650 | _ | 7 | |0 0 |2 NLM Chemicals |a Pyrazoles |
650 | _ | 7 | |0 0 |2 NLM Chemicals |a trimer-TEG-D3 |
650 | _ | 7 | |2 WoSType |a J |
653 | 2 | 0 | |2 Author |a aggregation |
653 | 2 | 0 | |2 Author |a amyloid beta peptides |
653 | 2 | 0 | |2 Author |a drug design |
653 | 2 | 0 | |2 Author |a molecular recognition |
653 | 2 | 0 | |2 Author |a peptides |
700 | 1 | _ | |0 P:(DE-Juel1)VDB95646 |a März-Berberich, J. |b 1 |u FZJ |
700 | 1 | _ | |0 P:(DE-HGF)0 |a Andrjevna, A. |b 2 |
700 | 1 | _ | |0 P:(DE-HGF)0 |a Rönicke, R. |b 3 |
700 | 1 | _ | |0 P:(DE-Juel1)VDB65461 |a Bartnik, D. |b 4 |u FZJ |
700 | 1 | _ | |0 P:(DE-Juel1)VDB89561 |a Brener, O. |b 5 |u FZJ |
700 | 1 | _ | |0 P:(DE-Juel1)VDB95649 |a Kutzsche, J. |b 6 |u FZJ |
700 | 1 | _ | |0 P:(DE-HGF)0 |a Horn, A.H.C. |b 7 |
700 | 1 | _ | |0 P:(DE-HGF)0 |a Hellmert, M. |b 8 |
700 | 1 | _ | |0 P:(DE-HGF)0 |a Gottmann, K |b 9 |
700 | 1 | _ | |0 P:(DE-HGF)0 |a Reymann, K. |b 10 |
700 | 1 | _ | |0 P:(DE-Juel1)VDB65869 |a Funke, S. A. |b 11 |u FZJ |
700 | 1 | _ | |0 P:(DE-Juel1)VDB72731 |a Nagel-Steger, L. |b 12 |u FZJ |
700 | 1 | _ | |0 P:(DE-HGF)0 |a Moriscot, C. |b 13 |
700 | 1 | _ | |0 P:(DE-HGF)0 |a Schoehn, G. |b 14 |
700 | 1 | _ | |0 P:(DE-HGF)0 |a Sticht, H. |b 15 |
700 | 1 | _ | |0 P:(DE-Juel1)132029 |a Willbold, D. |b 16 |u FZJ |
700 | 1 | _ | |0 P:(DE-Juel1)VDB77919 |a Schrader, T. |b 17 |u FZJ |
700 | 1 | _ | |0 P:(DE-HGF)0 |a Korth, C. |b 18 |
773 | _ | _ | |0 PERI:(DE-600)2011836-3 |a 10.1002/anie.201004437 |g Vol. 49, p. 8743 - 8746 |p 8743 - 8746 |q 49<8743 - 8746 |t Angewandte Chemie / International edition |v 49 |x 0044-8249 |y 2010 |
856 | 7 | _ | |u http://dx.doi.org/10.1002/anie.201004437 |
909 | C | O | |o oai:juser.fz-juelich.de:12405 |p VDB |
913 | 1 | _ | |0 G:(DE-Juel1)FUEK409 |a DE-HGF |b Gesundheit |k P33 |l Funktion und Dysfunktion des Nervensystems |v Funktion und Dysfunktion des Nervensystems |x 0 |
913 | 1 | _ | |0 G:(DE-Juel1)FUEK505 |a DE-HGF |b Schlüsseltechnologien |k P45 |l Biologische Informationsverarbeitung |v BioSoft: Makromolekulare Systeme und biologische Informationsverarbeitung |x 1 |
914 | 1 | _ | |a Angew Chem Int Ed Engl 2010 Nov.8; 49(46): 8743-6 |y 2010 |
915 | _ | _ | |0 StatID:(DE-HGF)0010 |2 StatID |a JCR/ISI refereed |
915 | _ | _ | |0 StatID:(DE-HGF)0030 |2 StatID |a Peer review |
915 | _ | _ | |0 StatID:(DE-HGF)0100 |2 StatID |a JCR |
915 | _ | _ | |0 StatID:(DE-HGF)0111 |2 StatID |a WoS |b Science Citation Index Expanded |
915 | _ | _ | |0 StatID:(DE-HGF)0150 |2 StatID |a DBCoverage |b Web of Science Core Collection |
915 | _ | _ | |0 StatID:(DE-HGF)0199 |2 StatID |a DBCoverage |b Thomson Reuters Master Journal List |
915 | _ | _ | |0 StatID:(DE-HGF)0300 |2 StatID |a DBCoverage |b Medline |
920 | 1 | _ | |0 I:(DE-Juel1)VDB942 |d 31.12.2010 |g ISB |k ISB-3 |l Strukturbiochemie |x 0 |
970 | _ | _ | |a VDB:(DE-Juel1)124021 |
980 | _ | _ | |a VDB |
980 | _ | _ | |a ConvertedRecord |
980 | _ | _ | |a journal |
980 | _ | _ | |a I:(DE-Juel1)ICS-6-20110106 |
980 | _ | _ | |a UNRESTRICTED |
981 | _ | _ | |a I:(DE-Juel1)IBI-7-20200312 |
981 | _ | _ | |a I:(DE-Juel1)ICS-6-20110106 |
Library | Collection | CLSMajor | CLSMinor | Language | Author |
---|